Kenya - English - Pharmacy and Poisons Board

sanofi-aventis kenya p.o box 20337 - 00200 nairobi kenya - clopidogrel - tablet - 75mg - antithrombotic agents: platelet aggregation

Namibia - English - Namibia Medicines Regulatory Council

sanofi-aventis south africa (pty) ltd - clopidogrel hydrogen sulphate - film-coated tablet - each film-coated tablet contains clopidogrel hydrogen sulphate equivalent to clopidogrel 300,0 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi winthrop industrie - clopidogrel (clopidogrel hydrosulfate) - tablets film-coated - 75mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - clopidogrel sulfate - white tablet, diameter: 6.8 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - clopidogrel sulfate - white tablet, diameter: 8.7 mm

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - aspirin 100mg; clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg clopidogrel;  ;   - film coated tablet - 75mg/100mg - active: aspirin 100mg clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg clopidogrel     excipient: carnauba wax colloidal silicon dioxide hydrogenated castor oil hyprolose macrogol 6000 maize starch mannitol microcrystalline cellulose opadry pink 32k24375 stearic acid - co-plavix is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: · unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia). coplavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, co-plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

European Union - English - EMA (European Medicines Agency)

hcs bvba  - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.